As we enter the second half of 2024, we are more steadfast than ever in our commitment to delivering innovative therapies for liver disease patients. Last month, we initiated our second Phase 3 clinical trial in #MASH in our ENLIGHTEN program. These two clinical trials, along with our ongoing Phase 3 trial in #SHTG, will evaluate the safety and efficacy of our investigational #FGF21 analog and bring us one step closer to delivering this potential best-in-class therapy to patients. Learn more about the recent advancements we’ve made in our clinical development pipeline: https://lnkd.in/guaY8Zz #MASH #Innovation #SHTG
89bio
Biotechnology Research
San Francisco, CA 9,335 followers
Developing and commercializing innovative therapies for the treatment of liver and cardio-metabolic diseases
About us
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG. 89bio is headquartered in San Francisco with operations in Herzliya, Israel. Our culture is best described by our values: • Always putting the patient first • Operating with the highest integrity and ethical standards at all times • Being authentic in all our transactions • Acting as a team – collaborating, respecting and caring for one another • Being entrepreneurial and passionate in our tasks • Being scientific and rational in our thought process and decision-making
- Website
-
http://www.89bio.com
External link for 89bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Francisco, CA
- Type
- Public Company
- Founded
- 2018
- Specialties
- Biopharmaceutical
Locations
-
Primary
Get directions
San Francisco, CA, US
Employees at 89bio
Updates
-
Our CEO, Rohan Palekar, and Dr. Arun Sanyal from Virginia Commonwealth University recently joined Simon Wentworth on The Pharma Letter Podcast to discuss the #MASH landscape and what’s next for 89bio and our lead therapeutic candidate. Tune in to the podcast episode to hear their discussion!
The Pharma Letter Podcast — Episode 28 — Breakthroughs in MASH, with 89bio CEO https://lnkd.in/dKtCiHpF
-
Yesterday was Global #FattyLiverDay! At 89bio, we remain dedicated to advancing research and developing our innovative treatment for patients with #MASH, a severe form of fatty liver disease. It is important to continue raising awareness of this chronic, progressive disease which fat accumulates in the liver, ultimately leading to fibrosis (or scarring). MASH is often a silent disease with few or no symptoms, making it particularly dangerous as it can lead to more severe liver damage, including cirrhosis and liver cancer if left unchecked. Learn more about MASH, and why early screening is important from Global Liver Institute: https://lnkd.in/gSCgcPJh
-
In case you missed it, we recently presented our latest research in #MASH at the 2024 #EASLCongress. This year’s congress was a great success, filled with collaborative discussions and innovative ideas aimed at improving patient outcomes in liver diseases. Thank you to everyone who listened in on our poster and oral presentations and engaged in meaningful conversations with our team. For more information, read our poster: https://lnkd.in/ge-cQQk5 #ICYMI #MASH
-
-
#EASLCongress begins tomorrow in Milan, where we will take the stage to present our latest findings in #MASH research. We’re excited to take part in this opportunity and discuss the latest innovations that may improve the lives of patients with liver diseases. Learn more: https://lnkd.in/gikxitnV #Innovation #EASLCongress
-
-
We’re excited to be presenting data from our Phase 2b ENLIVEN study in #MASH at the upcoming European Association for the Study of the Liver 2024 Congress. To learn more about our data presentations, read our release: https://lnkd.in/gikxitnV #Innovation #EASLCongress
-
-
We’re excited to announce the initiation of our second Phase 3 clinical trial in #MASH – ENLIGHTEN-Cirrhosis. This marks the first Phase 3 trial to evaluate the efficacy and safety of an investigational FGF21 analog in MASH patients with compensated cirrhosis (F4). To learn more about the trial, read our release: https://lnkd.in/gZn3dkZr #ClinicalTrials #Innovation
-
-
We are thrilled to host this upcoming webinar featuring Arun Sanyal, MD! You don’t want to miss it, so be sure to register below and tune in on Thursday, May 16th at 10:00 am ET.
Join 89bio (#ETNB) for a virtual KOL event on Thurs. May 16 at 10am ET featuring Arun J. Sanyal, MD (Virginia Commonwealth University), who will discuss the unmet need and current treatment landscape for advanced metabolic dysfunction-associated steatohepatitis (#MASH) patients with fibrosis and compensated cirrhosis. Register here: https://brnw.ch/21wJAaP
-
-
Today we announced our Q1 2024 financial results and business update. Read our release for the details: https://lnkd.in/g5xf9hnP
-
-
Looking forward to attending the Bank of America Merrill Lynch Securities Health Care Conference in Las Vegas, where we will be presenting and participating in meaningful conversations with investors and MASH key opinion leaders. For more information about our upcoming presentation, read our release: https://lnkd.in/guksT6Ss #MASH #Innovation
-